ReproCELL Inc. (4978) said it completed payment on Oct. 20, 2026 for its fourth third-party allotment to CVI Investments, Inc., issuing 2,932,000 new shares at ¥119 each for ¥348.9 million, alongside 29,320 units of its 20th series stock acquisition rights.
The issuance, approved by the board on Oct. 5, was the fourth under an Equity Program Agreement with CVI Investments. Capital and capital reserve each rose by ¥174.5 million, or ¥59.5 per share.
The warrants were issued at ¥117 each, for a total of ¥3.43 million, and represent 2,932,000 potential shares at 100 shares per warrant. The exercise price is fixed at ¥159 per share, with no reset mechanism and therefore no upper or lower exercise price. Full exercise at the initial price would bring in ¥469.6 million; that amount would change if the exercise price is adjusted, and fall if warrants go unexercised or are acquired and canceled by the company.
With the fourth payment, all share and warrant issuances under the program are complete. ReproCELL withdrew the shelf registration filed on May 27, 2026, citing the end of the planned offerings. The registration covered the period from June 4, 2026 to June 3, 2027.
| Item | Shelf cap | Offering results |
|---|---|---|
| Common shares (issue price) | ¥2.4 billion | ¥1.46 billion |
| Warrants (issue price) | ¥100 million | ¥14.7 million |
| Warrants incl. exercise amounts | ¥3.2 billion | ¥1.96 billion |
The 20th series warrants are exercisable from Oct. 21, 2026 to Oct. 18, 2030.
| Hikari Tsushin, Inc. | |
| Offer price | ¥1,000 per common share |
| M&A / TOB | 1 |
| Guidance | 0 |
| Buybacks | 0 |
| Dividends | 0 |
| Capital | 0 |
| Earnings | 0 |
| People | 0 |
Summaries of public disclosures by Japanese listed companies. Not investment advice; accuracy not guaranteed. Figures and dates in the TDnet originals prevail.
本站內容為日本上市公司公開開示之摘要整理，非投資建議，亦不保證正確。數字與日程以 TDnet 原文為準。
本サイトは日本の上場企業の適時開示を要約したものであり、投資助言ではありません。正確性は保証しません。数値・日程は TDnet の原文が優先します。